Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects:

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 3. by Rahsan Erdem (11726357)

Subjects:

Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate. by Rahsan Erdem (11726357)

Subjects:

Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Scatterplot of the incidence rate of tuberculosis (TB) in 1990 versus (a) the cumulative mortality rate of COVID-19 and (b) the cumulative incidence rate of COVID-19 on 5 April 202... by Kazuo Inoue (302545)

Scatterplot of the mortality rate of tuberculosis (TB) in 1950 versus (a) cumulative mortality rate of COVID-19 and (b) the cumulative incidence rate of COVID-19 on 5 April 2020, a... by Kazuo Inoue (302545)

Percentage of Saudi subjects carrying actionable variants in zero to five pharmacogenomics genes. by Ewa Goljan (3463487)

Subjects:

The global disease burden of <i><i>Klebsiella pneumoniae</i></i> associated LRI for both sexes in 204 countries and territories. (a) The number of DALYs in 2021; (b) The EAPC of DA... by Juanjuan Li (399633)

S5 Fig - by Meghan J. Hirsch (16528311)

“…Our model shows with an inoculum of 2 x 10² CFUs of PA for 24 hours pro-inflammatory markers such as interleukin 6 and interleukin 8 are upregulated with little decrease in CF bronchial epithelial cell survival or monolayer confluency. …”

NSUN2 positively regulates HBV expression and replication by maintaining RNA stability. by Jiangpeng Feng (9287738)

Subjects:

NSUN2 positively regulates HBV expression and replication <i>in vivo</i>. by Jiangpeng Feng (9287738)

Subjects:

Excel spreadsheet containing, in separate sheets (for each figure), the underlying numerical datas for Figure panels 1A, 1B, 1C, 2B, 3A, 3B, 3C, 4C, 4D, 4E, 4F, 4G, 5B, 8C and 8D. by Acharya Balkrishna (5640038)